Involvement of FFA Metabolism and Insulin Resistance in Cardiac Death

NCT01068080 | Completed

• 1 other identifier: Toujinkai Clincal Study-2
• Study Type: observational
• Target: 155
• Locations: 1 country
• Sites: 1

Brief Summary

The investigators evaluated predictive values of myocardial fatty acid metabolism and insulin resistance for cardiac death of hemodialysis patients with normal coronary arteries.

Conditions

Kidney Disease; Coronary Artery Disease; Hemodialysis

Keywords

fatty acid metabolism; insulin resistance; cardiac death; hemodialysis; normal coronary arteries; Predictive values of impaired myocardial fatty acid metabolism or insulin resistance for cardiac death of hemodialysis patients with normal coronary arteries

Outcome Measures

Primary Outcomes (1)

• Cardiac death

Secondary Outcomes (1)

• All-cause death

Study Arms (1)

Myocardial fatty acid metabolism, Insulin resistance

Myocardial fatty acid metabolism was evaluated by myocardial fatty acid imaging using BMIPP SPECT. Insulin resistance was evaluated by HOMA-IR.

Eligibility Criteria

• Age: 40 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Hemodialysis patients who had normal coronary arteries identified by coronary angiography and underwent the examination of BMIPP SPECT and measurement of HOMA-IR as a parameter of insulin resistance.

You may qualify if:

• Hemodialysis patients who had normal coronary arteries identified by coronary angiography and underwent the examination of BMIPP SPECT and measurement of HOMA-IR as a parameter of insulin resistance.

You may not qualify if:

• Patients who had not done BMIPP SPECT within one month of coronary angiography
• Congestive heart failure (NYHA 3-4)
• Significant valvular heart disease
• Pacemaker
• Idiopathic cardiomyopathy
• Malignancy
• Patients who had not measured HOMA-IR within one month after coronary angiography
• Patients receiving extrinsic insulin or medication of sulfonylurea

Sponsors & Collaborators

• Toujinkai Hospital: lead

Study Sites (1)

Toujinkai Hospital

Kyoto, Kyoto, 612-8026, Japan

Location

Related Publications (1)

• Nishimura M, Okamoto Y, Takatani T, Sato N, Nishida M, Hashimoto T, Yamazaki S, Kobayashi H, Ono T. Improvement of myocardial fatty acid metabolism by oral nicorandil in hemodialysis patients without coronary artery disease. J Nephrol. 2015 Apr;28(2):227-34. doi: 10.1007/s40620-014-0125-5. Epub 2014 Jul 29.

  PMID: 25070153 DERIVED

MeSH Terms

Conditions

Kidney Diseases; Coronary Artery Disease; Insulin Resistance; Death

Condition Hierarchy (Ancestors)

Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Toshihiko Ono, MD

  Toujinkai Group

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: February 11, 2010
• First Posted: February 12, 2010
• Study Start: January 1, 2001
• Study Completion: December 1, 2004
• Last Updated: February 12, 2010

Record last verified: 2000-10

Locations

JP (1)